Biotech Stocks

Maxim Reiterates ‘Buy’ On Inovio Pharmaceuticals, Adjusts Price Target

In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.

Canaccord Reiterates Buy, $45 Price Target on Alere

Canaccord analyst Mark Massaro maintains his Buy rating and $45 price target on Alere (ALR) following the news that Alere has decided not to pursue an IPO …

Roth Capital Maintains Buy Rating On Tonix Following A Physician Conference Call

In a research note issued today, Roth Capital analyst Scott Henry maintained coverage with a “Buy” rating on Tonix Pharmaceuticals Holding Corp (TNXP) and a …

Roth Capital Raises Price Target On EnteroMedics Following FDA Panel Recommendation

In a research note issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating and boosted his price target on EnteroMedics Inc. (ETRM) to $5.

Roth Capital Initiates Coverage On Prosensa At Neutral; Sets $12 Price Target

In a research note released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage with a “Neutral” rating on Prosensa Holding N.V.

Seeking Alpha Article On Ligand Pharmaceuticals Just Foolish, Says Roth Capital Analyst

A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based …

Galena Reiterated With A Buy At Roth Capital Following Enrollment Completion In Phase IIa Study

In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …

Roth Capital Reiterates Buy Rating On Can-Fite Following The Completion Of Patients Enrollment

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated coverage on Can-Fite Bio Pharma (CANF) with a Buy rating and a $28.00 price target.

H.C. Wainwright Keeps ‘Buy’ On Ariad Following $200 Million Offering

In a research note issued today, H.C.

Agile Initiated With A Buy At Janney Capital; Considers AGRX A Compelling Investment

Janney Capital analyst Kimberly Lee is out today with an interesting call initiating Agile Therapeutics, Inc. (AGRX) with a Buy rating and $18 fair …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts